BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...2 Lauren Martz Aduhelm, aducanumab (BIIB037) sotorasib (AMG 510) MRTX849 Mirati Therapeutics Inc. Tumor-associated calcium signal transducer 2 (TROP2) (TACSTD2) (EGP-1) T...
BioCentury | Sep 15, 2020
Product Development

Data Bytes: Trodelvy leads TROP2 pack

...1 ligand 1 TROP2 (TACSTD2; EGP-1) - Tumor-associated calcium signal transducer 2 Amanda Micklus Gilead Sciences Inc. Immunomedics Inc. Tumor-associated calcium signal transducer 2 (TROP2) (TACSTD2) (EGP-1) Oncology TROP2 combinations acquisitions deals...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

FDA's ODAC may have given the thumbs down to Daiichi’s quizartinib, but a stocked pipeline and another ongoing trial of the candidate suggest it’s more of a hiccup than a hurdle in the Japanese pharma’s...
Items per page:
1 - 4 of 4